Dr. Ned McNamee said the RIOMeso study is the first detailed report of real-world outcomes in Australian patients undergoing ipi + nivo treatment for pleural meso. Read more
The initiatives include a $2.5 million, 4-year research grant and projects to improve lung cancer biomarker testing uptake around the world. Read more
Patient research advocate Angus Pratt reflects on the past year of advocacy coverage in ILCN and how the movement has evolved in recent years. Read more
Researchers evaluating the clinical significance of IASLC-proposed criteria found the recommendations better align with clinicopathologic risk factors and improve prognostication. Read more
The association recommends collecting data on tobacco use status to advance knowledge on the impacts of tobacco smoke in the context of cancer clinical trials. Read more
Patient Perspective: Patients With EGFR+ NSCLC May Still Opt for Quality Over Quantity After FLAURA2
In light of recent data from the study of osimertinib with or without chemotherapy, patient advocate Ivy Elkins said the results may sway some to add chemo to their first-line treatment plan. However, for others, the impact on quality of life will not be worth it. Read more
When novel agents demonstrate high rates of durable treatment response but comparative outcome data with standard treatments are lacking, it is important to have methods to translate those treatments to different settings. Read more
During the 2023 World Conference on Lung Cancer, Dr. Stephen Chun said long-term data show intensity-modulated radiation therapy offers an overall survival benefit and reduced toxicity compared to 3D conformal radiation therapy. Read more
LungCAN Co-Chair Dusty Donaldson says training program helped just two advocates reach more than 630 million people in 32 states and five countries. Read more
Dr. Jennifer King brings expertise in molecular targets for cancer therapeutics as well as executive-level experience implementing strategic initiatives to the scientific affairs team. Read more